Autolus Therapeutics (AUTL) Revenue & Revenue Breakdown
Autolus Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.70M
Main Segment (Y)
License
Main Geography (Y)
UNITED STATES
Autolus Therapeutics Revenue by Period
Autolus Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $1.70M | -72.59% |
2022-12-31 | $6.19M | 165.84% |
2021-12-31 | $2.33M | 862.81% |
2020-12-31 | $242.00K | -91.68% |
2019-12-31 | $2.91M | 178.19% |
2018-09-30 | $1.05M | -38.25% |
2017-09-30 | $1.69M | 39.69% |
2016-09-30 | $1.21M | - |
Autolus Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | -100.00% |
2024-03-31 | $10.09M | 468.51% |
2023-12-31 | $1.77M | 337.19% |
2023-09-30 | $406.00K | 100.00% |
2023-06-30 | - | -100.00% |
2023-03-31 | $1.29M | -66.22% |
2022-12-31 | $3.83M | 61.46% |
2022-09-30 | $2.37M | 100.00% |
2022-06-30 | - | -100.00% |
2022-03-31 | $166.00K | -79.83% |
2021-12-31 | $823.00K | 248.73% |
2021-09-30 | $236.00K | -84.34% |
2021-06-30 | $1.51M | 460.22% |
2021-03-31 | $269.00K | -130.81% |
2020-12-31 | $-873.00K | -460.74% |
2020-09-30 | $242.00K | -17.41% |
2020-06-30 | $293.00K | -13.31% |
2020-03-31 | $338.00K | 9.39% |
2019-12-31 | $309.00K | 4.04% |
2019-09-30 | $297.00K | -12.13% |
2019-06-30 | $338.00K | -82.79% |
2019-03-31 | $1.96M | 563.51% |
2018-12-31 | $296.00K | -3.58% |
2018-09-30 | $307.00K | -30.70% |
2018-06-30 | $443.00K | 3.99% |
2018-03-31 | $426.00K | 4.93% |
2017-09-30 | $406.00K | - |
2017-06-30 | $406.00K | -7.83% |
2017-03-31 | $440.50K | - |
2016-12-31 | $440.50K | - |
Autolus Therapeutics Revenue Breakdown
Autolus Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
---|---|---|---|---|
License | $1.70M | $3.50M | $242.00K | - |
Royalty | - | - | - | - |
Grant | - | $166.00K | $823.00K | $1.47M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 20 | Sep 20 |
---|---|---|---|---|
License | - | $10.10M | - | $242.00K |
Grant | - | - | $1.03M | $438.00K |
Latest
Autolus Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
UNITED STATES | $1.35M | $6.19M | $1.51M |
Latest
Quarterly Revenue by Country
Country | Mar 24 | Sep 20 |
---|---|---|
UNITED STATES | - | - |
GERMANY | $10.09M | - |
License | - | $242.00K |
Grant | - | $438.00K |
Latest
Autolus Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
VECT | VectivBio | $27.34M | $676.00K |
IKNA | Ikena Oncology | $9.16M | - |
BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
AUTL | Autolus Therapeutics | $1.70M | - |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
MNOV | MediciNova | $1.00M | - |
ANEB | Anebulo Pharmaceuticals | - | - |
RZLT | Rezolute | - | - |
CGEM | Cullinan Oncology | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |
CELC | Celcuity | - | - |